Phase II Bevacizumab + Tax In Advanced Breast Cancer
Completed · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: This randomized phase II trial is to see if docetaxel with or without bevacizumab followed by surgery, radiation therapy, and combination chemotherapy works better in treating patients who have stage III or stage IV breast cancer.
Key facts
- Study ID
- NCT00027885
- Run by
- Case Comprehensive Cancer Center
- People needed
- 49
- Starts
- 2001-11-01
- Expected to finish
- 2010-08-01
- Last updated by the study team
- 2013-06-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center — Cleveland, Ohio, United States
- UH-Southwest — Middleburg Heights, Ohio, United States
- UH-Chagrin Highlands — Orange, Ohio, United States
- UH-Green Road — South Euclid, Ohio, United States
- UH-Westlake — Westlake, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.